Literature DB >> 8677900

Prognostic factors of locoregionally recurrent nasopharyngeal carcinoma--a retrospective review of 182 cases.

T S Yang1, K T Ng, H M Wang, C H Wang, C C Liaw, G M Lai.   

Abstract

Locoregional relapse is the major cause of failure of nasopharyngeal carcinoma (NPC) after radical radiation therapy. The prognosis of such patients is dismal, and the factors related to the outcome are not well identified. Between January 1983 and December 1989, 1,168 new patients with biopsy-proven NPC were seen at this hospital. Eight hundred and eighty-three of these patients were treated uniformly with radical external irradiation and intracavitary treatment with or without chemotherapy. The clinical courses, retreatment outcomes, and prognostic factors for locoregional relapse and subsequent distant metastasis were analyzed. During the follow-up period of 3-10 years or until death, 182 patients (20.6%) developed locoregional relapses without distant metastasis initially. T stage and age were significant prognostic factors for locoregional recurrence. In contrast, histopathologic subtype, N stage, sex, and systemic chemotherapy were not. There were 36 patients (19.8%) who developed subsequent distant metastasis with or without retreatment. The median time from locoregional relapses to distant metastasis was 6 months in this study, and bone was the most frequent and the earliest site of distant metastasis. The N stage at diagnosis, the initial disease-free interval, the presence of neck nodal disease at relapse, and age were the significant factors for predicting the subsequent distant metastasis in locoregionally recurrent NPC patients. We recommend that additional systemic chemotherapy should be considered for retreatment of locoregional relapsed NPC, not only for enhancement of local control but also for eradicating microscopic metastasis as anticipated.

Entities:  

Mesh:

Year:  1996        PMID: 8677900     DOI: 10.1097/00000421-199608000-00003

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  11 in total

Review 1.  Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.

Authors:  Tao Xu; J Tang; M Gu; L Liu; W Wei; H Yang
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

2.  Prediction of local recurrence and distant metastasis using radiomics analysis of pretreatment nasopharyngeal [18F]FDG PET/CT images.

Authors:  Lihong Peng; Xiaotong Hong; Qingyu Yuan; Lijun Lu; Quanshi Wang; Wufan Chen
Journal:  Ann Nucl Med       Date:  2021-02-04       Impact factor: 2.668

3.  Value of 18F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence.

Authors:  Seung Hwan Moon; Young Seok Cho; Young-Ik Son; Yong Chan Ahn; Myung-Ju Ahn; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Br J Radiol       Date:  2016-09-21       Impact factor: 3.039

4.  MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expressions.

Authors:  Yu Zhu; Chunlin Zou; Zhe Zhang; Chao-Nan Qian; Xin Yang; Junlin Shi; Yudui Xia; Jian Zhang; Yi Lu
Journal:  Tumour Biol       Date:  2015-06-10

5.  Molecular markers to assess short-term disease local recurrence in nasopharyngeal carcinoma.

Authors:  Tao Xu; Bojin Su; Chunhua Wang; Sumei Wang; Hecheng Huang; Yunbao Pan; Donghui Wang; Weihong Wei; François X Claret; Huiling Yang
Journal:  Oncol Rep       Date:  2015-01-20       Impact factor: 3.906

Review 6.  The role of microRNAs in nasopharyngeal carcinoma.

Authors:  Gongjun Tan; Xiaowei Tang; Faqing Tang
Journal:  Tumour Biol       Date:  2014-11-27

7.  Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma.

Authors:  San Jiun Chai; Yoke Yeow Yap; Yoke Ching Foo; Lee Fah Yap; Sathibalan Ponniah; Soo Hwang Teo; Sok Ching Cheong; Vyomesh Patel; Kue Peng Lim
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

8.  Site-specific localization of Epstein-Barr virus in pharyngeal carcinomas.

Authors:  S Kojya; T Itokazu; Y Noda; M Ezaki; Y Tomita; M Ohsawa; K Aozasa
Journal:  Jpn J Cancer Res       Date:  1998-05

9.  PPARβ/δ Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma in C666-1 Cells by Promoting Apoptosis.

Authors:  Yangyang Ji; Hui Li; Fang Wang; Linglan Gu
Journal:  Front Pharmacol       Date:  2018-06-28       Impact factor: 5.810

10.  Diagnostic value of diffusion-weighted magnetic resonance imaging for local and skull base recurrence of nasopharyngeal carcinoma after radiotherapy.

Authors:  Chen Wang; Lidong Liu; Shaolv Lai; Danke Su; Younan Liu; Guanqiao Jin; Xuna Zhu; Ningbin Luo
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.